First antibody trial launched in COVID-19 patients

First antibody trial launched in COVID-19 patients

The article describes the initiation of the first clinical trial (ClinicalTrials.gov LY-CoV555) that uses monoclonal antibody binding S-protein of SARS-Cov-2 virus. The antibody was designed using the most potent clones of B cells from COVID-19 patients. Before vaccine available the access to the highly specific monoclonal antibody would be very useful and might enrich treatment strategies in COVID-19.

This article was selected by Adam Klocperk, Marketa Bloomfield, Tomáš Milota, and Anna.